<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095301</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1320</org_study_id>
    <nct_id>NCT02095301</nct_id>
  </id_info>
  <brief_title>Herbal Extract Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effects of an herbal extract on mental energy in
      healthy human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the ratings from computer administered tasks within the domains of mood, short-term recognition memory, and attention from pre- to post-study product consumption and between treatment conditions of an herbal extract</measure>
    <time_frame>0-2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure plasma nutrient metabolites</measure>
    <time_frame>0-7 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Normal Controls</condition>
  <arm_group>
    <arm_group_label>Control plus herbal extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control plus herbal extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine-free, carbonated soft drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Caffeine-free, carbonated soft drink</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Herbal Beverage</intervention_name>
    <arm_group_label>Control plus herbal extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is male or female, 18-70 years of age, inclusive.

          2. Subject has a body mass index (BMI) ≥17.0 and ≤32.9 kg/m2 at visit 1 (day -14 to -2).

          3. Subject has no health conditions that would prevent him/her from fulfilling the study
             requirements as judged by the Investigator on the basis of medical history, and
             routine laboratory test results.

          4. Subject is a non-smoker, defined as no tobacco use for ≥6 months prior to visit 1 (day
             -14 to -2).

          5. Individual is willing to maintain a habitual diet and physical activity patterns
             throughout the study period.

          6. Subject is willing to consume study product and standardized meals.

          7. Individual is willing to abstain from caffeinated beverages and other
             caffeine-containing products for 12 h prior to all test visits (visits 2, 3, and 4;
             days 0, 3, and 6).

          8. Subject is willing to abstain from alcohol consumption and avoid non-routine vigorous
             physical activity for 24 h prior to all test visits (visits 2, 3, and 4; days 0, 3,
             and 6).

          9. Subject is willing to discontinue any vitamin/mineral or dietary supplements use for 2
             weeks prior to visit 2 (day 0) and throughout the study period.

         10. Subject is a female who is willing to schedule the randomization visit (visit 2, day
             0) during the luteal phase of her menstrual cycle, defined as days 15 to the end of
             the cycle, where day 1 is the first day of menses, where appropriate.

         11. Subject understands the study procedures and signs forms providing informed consent to
             participate in the study and authorization for release of relevant protected health
             information to the study Investigator.

        Exclusion Criteria:

          1. Subject is unable to understand and/or perform required tests and questionnaires
             (i.e., subjects cannot complete the practice tests, or tasks).

          2. Subject is color blind.

          3. Subject has an abnormal laboratory test result of clinical significance, including,
             but not limited to creatinine ≥1.5 mg/dL and ALT or AST ≥1.5X upper limit of normal at
             visit 1 (day -14 to -2).

          4. Subject has a known allergy or sensitivity to study products or any ingredients of the
             study products, standardized meals/snacks provided.

          5. Subject has a gastrointestinal condition that could potentially interfere with
             absorption of the study product (e.g., inflammatory bowel syndrome, celiac disease,
             history of gastric bypass surgery).

          6. Subject has diagnosed depression, schizophrenia, or dementia in the last 2 years prior
             to visit 1 (day -14 to -2).

          7. Subject has a history or presence of clinically important cardiac (including, but not
             limited to, atherosclerotic disease, history of myocardial infarction, peripheral
             arterial disease, and/or stroke), renal, hepatic, endocrine (including type 1 or type
             2 diabetes mellitus), pulmonary, biliary, pancreatic, or neurologic disorders.

          8. Subject has extreme dietary habits (e.g., vegan, Atkins diet, very high protein).

          9. Subject has uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic
             blood pressure ≥100 mm Hg as defined by the blood pressure measured at visit 1, (day
             -14 to -2). One re-test will be allowed on a separate day prior to visit 2 (day 0) for
             subjects whose blood pressure exceeds either of these cut points at visit 1.

         10. Subject has a history or presence of cancer in the prior 2 years, except for
             non-melanoma skin cancer.

         11. Subject has signs/symptoms of an active infection of clinical relevance (e.g., urinary
             tract or respiratory infection). Test visits (visits 2, 3, and 4; days 0, 3, and 6)
             will be re-scheduled to allow subject to be symptom-free of any type of systemic
             infection for at least 5 d.

         12. Subject has recently used antibiotics (within 5 d of any test visit; Appendix 1). Test
             days (visits 2, 3, and 4; days 0, 3, and 6) will be rescheduled to allow the subject
             to be free of antibiotic therapy for at least 5 d.

         13. Subject has a history of use of psychotropic medications within 6 months of visit 2
             (day 0) and throughout study period.

         14. Subject has used any other prescription medications, including over-the-counter
             medications within 2 weeks of visit 2 (day 0; Appendix 1) and throughout study period.

         15. Subject has used any over-the-counter or prescription sleep aid products (including
             dietary supplements) within 2 weeks of visit 2 (day 0) and throughout study period.

         16. Subject has a diagnosed sleep disorder (e.g., sleep apnea) or occupation where sleep
             during the overnight hours is irregular (e.g., 3rd shift or overnight workers).

         17. Subject consumes excessive amounts of caffeine (&gt;4 cups of caffeinated coffee/d or
             &gt;400 mg caffeine/d from caffeine-containing products).

         18. Subject is a female, who is pregnant, planning to be pregnant during the study period,
             lactating, or is of childbearing potential and is unwilling to commit to the use of a
             medically approved form of contraception throughout the study period. The method of
             contraception must be recorded in the source document.

         19. Subject has a recent history of (within 12 months of screening; visit 1, day -14 to
             -2) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as
             &gt;14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).

         20. Subject has been exposed to any non-registered drug product within 30 d prior to
             screening.

         21. Individual has a condition the Investigator believes would interfere with his or her
             ability to provide informed consent, comply with the study protocol, which might
             confound the interpretation of the study results or put the person at undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anil Samsong</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

